Bio-tech company New Horizon Health received USD 20 M for Series A+
New Horizon Health
Founder: Zhu Yeqing
Founded in: 2016
Financing status: RMB 133 million (USD 20 million) for Series A+ financing in 2017
Bio-tech company New Horizon Health received USD 20 M for Series A+ on August 9 to improve its development of new cancer treatments.
Though on average we tend to enjoy a longer and better quality life, cancer is still a looming threat. A major reason cancer is so deadly is that it is often detected too late. For example, colorectal cancer–one of the most commonly occurring cancers–has a 100% cure rate in its precancerous stage and 90% in its early stage. Patients are more likely to be cured if they can detect cancers early. There are some barriers to early detection, such as precision and the cost of cancer diagnoses, and that is where innovative bio-tech companies come in.
New Horizon Health is a bio-tech company that provides patients with screening and testing services for high-risk cancers. It integrates gene detection with molecular diagnosis technology, and combines online big data application platforms in order to establish a self-help system. This system allows it to help more patients detect high incidences of cancer in the early stages, and thereby increase their chances of being cured. At the same time, it is able to reduce medical costs and improve medical efficiency.
Founded in 2016 in Hangzhou, New Horizon Health currently works with hospitals and other research institutions to promote its cancer screening and test services. Additionally, it offers patients a competitive price based on its promotion across China. The more people start to detect cancers through its platform, the lower the cost of its research and the development of its cancer test services becomes.
This new financing round was led by Qiming Venture Partners, with Legend Capital and Soft Bank China Capital participating as investors. The capital will be used to invest in the research and development of new cancer detection and treatment technologies, as well as to acquire partners across China to promote its cancer screening and test services.
City express delivery services provider Shansong received undisclosed Series C+
Shansong
Founded in: 2014
Financing status: RMB 340 million (USD 50 million) for Series C+ financing in 2017
City express delivery services provider, Shansong, received undisclosed Series C+ on August 8 to recruit more employees to expand its business into more cities.
Shansong is a city express delivery services provider that provides short-distance and same-city express delivery services. Unlike traditional logistics systems that transport packages and other goods from one station to another through multiple employees, Shansong assigns a delivery task to one courier who is responsible for the whole delivery process. This new model can save time on delivery and improve security.
According to data provided by the company, customers receive replies within one minute after they place their orders online. The average delivery time within 5 km in Beijing is 23 minutes, and orders within 10 km can be delivered within 33 minutes.
Founded in 2014 in Beijing, the company has so far attracted over 30 million users across China. Currently, its services are available in 50 cities across China, and it does over 100,000 deliveries daily with an average price of RMB 35 per order.
Shansong previously received funding from Shunwei Capital, Macrolink Group, Hearst Magazine China, and Prometheus Capital. This Series C+ financing round was led by Westsummit Capital. Shansong plans to use the funds to recruit more employees to expand its business across China and introduce new technology, such as big data technology, to boost the efficiency of its services.
（Top photo from 58pic.com）
